Myomo

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. It offers MyoPro, an upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myomo reports 9% revenue growth in Q1 2024 earnings call

Myomo's Q1 2024 performance reflects revenue growth driven by favorable CMS developments, with plans to double manufacturing capacity and achieve cash flow breakeven by Q4 2024.
The company's strategic strengths lie in its focus on the prevalence group, international expansion, and commitment to market leadership through increased output and R&D investments.
Challenges include managing operating expenses, scaling manufacturing capacity, and meeting revenue targets amidst market competition and reimbursement rate fluctuations.
Opportunities abound in international growth, market expansion in Germany, and the potential for accelerated U.S. revenue, supported by investments in resources and R&D.

Myomo excels in Q2 with record revenues and global expansion

Myomo's Q2 2024 performance reflects strong revenue growth, operational efficiency gains, and strategic expansion initiatives.
The company's strengths lie in international revenue generation, production facility expansion plans, and commitment to meeting product demand.
Challenges include scaling production while ensuring quality, monitoring advertising ROI, and balancing R&D with operational needs.
Opportunities arise from investor engagement, increased advertising, and continued innovation to drive market presence and revenue growth.

Myomo reports record Q3 revenue, eyes global expansion and market partnerships

Myomo's Q3 performance showcased robust revenue growth, pipeline expansion, and strategic partnerships, positioning the company for sustained success and global expansion.
While facing operational losses, Myomo's strengths in product innovation, market expansion, and capacity planning provide a solid foundation for future growth and profitability.
Challenges in cost management, market penetration, and regulatory compliance need to be addressed, but the company's proactive approach to expansion and partnerships bodes well for seizing growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The firm is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Myomo's management has a history of diluting shareholders. The firm is still burning cash. Therefore, I will pass on this stock. Myomo claims it will become cash flow positive in Q4 by increasing direct billing, but it has already done that in the past few years without getting to breakeven.

Why I Didn't Buy Myomo: Dilution And Cash Burn

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update regarding its application for a Healthcare Common Procedure Coding System (“HCPCS”) Level II code change and benefit category redetermination for HCPCS codes L8701 and L8702 submitted in January 2021. The Centers for Medicare & Medicaid S

Myomo Provides Update on CMS Discussions

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that CEO Paul R. Gudonis and CFO David Henry will present at the Summer Solstice – Best Ideas From the Buy Side Conference on June 1, 2021 at 2:30 p.m. Eastern time. The conference is sponsored by the Microcap Rodeo and will be held virtually June 1-4

Myomo to Present at the Summer Solstice - Best Ideas From the Buy Side Conference

Myomo has a revolutionary product that allows people with paralyzed arms to use them once more.

Myomo: Ridiculously Cheap Medtech

Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2021. Financial and operational highlights for the first quarter of 2021 include the following (all comparisons are with the first quarter of 2020, unless otherwise noted): Revenue was $2.3 millio

Myomo Reports First Quarter 2021 Financial Results

Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2021 on May 5, 2021 after the market close. The Company will host a conference call the same day, Wednesday, May 5, 2021 at 4:30 p.m. ET with prepared remarks by Paul R. Gudoni

Myomo to Report First Quarter 2021 Financial Results on May 5, 2021

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Thomas Jefferson University of Philadelphia has successfully completed the first phase of clinical trials using sensors imbedded in the brain to control a MyoPro powered brace worn by a stroke patient. The story is detailed in the University web

Myomo Participates in Ground-breaking Brain-computer Interface Trial

Myomo develops, manufactures, and sells a wearable medical device for stroke patients that lost control or strength in their arms. Myomo's recent quarter and future growth prospects look bright in part because they received the Medicare Certification.

Myomo, A High Risk And High Potential Investment At The Right Time

Myomo, Inc. (MYO) CEO Paul Gudonis on Q4 2020 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2020. Financial and operational highlights for the fourth quarter of 2020 include the following (all comparisons are with the fourth quarter of 2019, unless otherwise noted): Revenue w

Myomo Reports Fourth Quarter and Full Year 2020 Financial Results

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Myomo's CEO, and David Henry, Myomo's CFO will participate in three virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being

Myomo to Participate in Three Investment Conferences During the Month of March

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2020 on March 10, 2021 after the market close. The Company will host a conference call the same day, Wednesday, March 10, 2021 at 4:30 p.m. ET with prepared remarks

Myomo to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced Techniker Krankenkasse (TK), Germany's largest Statutory Health Insurance (SHI) company, now approves reimbursement of MyoPro on a case-by-case basis. TK covers over 10 Million insured lives and joins the ranks of other major German health insurance p

Germany's Largest Statutory Health Insurance Company Approves MyoPro

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the Winter Wonderland – Best Ideas from the Buy-side Conference. The conference is being held virtually on February 16th through February 19th. Myomo's presentation is scheduled for February 16th at 10:00 a.m.

Myomo to Present at the Winter Wonderland – Best Ideas from the Buy-side Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces the signing of a definitive agreement (the “JV Agreement”) with Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”) to form a joint venture (the “JV”) to manufacture and sell the Company's current and future products in greater China, inc

Myomo® Forms Joint Venture to Manufacture and Sell the Company's Products in China

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2020. In particular, Myomo expects revenue for the three months ended December 31, 2020 to more than double compared with the fourth quar

Myomo Reports Preliminary Fourth Quarter and Full Year 2020 Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, the Company's chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021. The presentation can be accessed at th

Myomo to Present H.C. Wainwright Virtual BioConnect 2021 Conference

Transmedics Group Inc

Exagen Inc

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be presenting at the Sidoti & Company Virtual Microcap Conference on Thursday, November 19, 2020 at 1:45 p.m. Eastern Time. The presentation will be webcast live and available for replay in the Investor Relations sec

Myomo to Present at Sidoti & Company Virtual Microcap Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering from neurological disorders and upper-limb paralysis, announced today the availability of MyoGames by Lusio, a video game platform designed to augment training and rehabilitation for MyoPro users, while being fun. MyoGames enables users to play video games by actively engaging their paralyzed or weakened ar

Myomo Introduces MyoGames™

Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q3 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2020. Financial and operational highlights for the third quarter of 2020 include the following (all comparisons are with the third quarter of 2019, unless otherwise noted):

News for Myomo Stock (MYO)